Aurinia Refocusing After Failed Effort To Find A Buyer

By Yeji Jesse Lee · February 15, 2024, 6:00 PM EST

Kidney-focused biotech Aurinia Pharmaceuticals is hitting pause on drug development, cutting jobs and initiating a $150 million stock buyback program, the company disclosed in its year-end financial report Thursday....

To view the full article, register now.